Mease PJ, Kellner H, Morita A, et al. Efficacy and Safety Results from a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor, in Patients with Active Psoriatic Arthritis. ACR 2017, abstract 2L.
Consortium ontvangt 1,8 miljoen euro van ZonMw voor studie naar beweegreis
sep 2024 | Artrose, RA